nct_id: NCT05473156
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-07-25'
study_start_date: '2023-07-24'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: AP203'
long_title: A Phase 1/2, Open-label Study of the Safety, Pharmacokinetics, and Clinical
  Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors,
  and Expansion to Selected Malignancies
last_updated: '2025-03-26'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: AP Biosciences Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 168
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- '* Dose escalation Phase and Dose expansion Phase Inclusion Criteria:'
- 1. Written informed consent by the participants or the participant's legally authorized
  representative prior to screening.
- 2. Participants with Eastern Cooperative Oncology Group (ECOG) performance status
  of 0 to 1 at study enrollment and an estimated life expectancy of at least 3 months.
- 3. Disease must have at least 1 measurable lesion by Response Evaluation Criteria
  in Solid Tumors (RECIST) version 1.1. Tumor lesions situated in a previously irradiated
  area are not considered measurable unless there has been demonstrated progression
  in the lesion. Imaging tests outside the screening period are valid if performed
  not more than 2 weeks before consent signature and otherwise fulfil protocol criteria.
- '4. Participants with adequate organ function defined by the following:'
- "Participants must not have required blood transfusion or growth factor support\
  \ \u2264 14 days before sample collection at screening:"
- "1. Absolute neutrophil count \u2265 1.5 \xD7 109 /L."
- "2. Platelet count \u2265 100 \xD7 109 /L."
- "3. Hemoglobin \u2265 9 g/dL."
- "4. Alanine aminotransferase and AST \u2264 2.5 \xD7 ULN or \\< 5 \xD7 ULN if hepatic\
  \ metastases present."
- "5. Serum total bilirubin \u2264 1.5 \xD7 ULN (or \\< 3 \xD7 ULN for participants\
  \ with Gilbert's syndrome)."
- "6. Alkaline phosphatase \u2264 2.5 \xD7 ULN or \\< 5 \xD7 ULN if bone metastases\
  \ present."
- "7. Prothrombin time \u2264 1.5 \xD7 ULN."
- "8. International normalized ratio (INR) \u2264 2.0 or activated partial thromboplastin\
  \ time (aPTT) \u2264 1.5 \xD7 ULN. Exception: INR 2 to \u2264 3 is acceptable for\
  \ participants on a stable dose of anticoagulants."
- 9. Estimated creatinine clearance \> 50 mL/min according to the Cockcroft Gault
  formula
- 5. Participants with highly effective contraception (that is, methods with a failure
  rate of less than 1% per year) for both male and female participants if the risk
  of conception exists.
- '* Dose escalation Phase specific Inclusion Criterion:'
- 1. Participants with histologically or cytologically proven locally unresectable
  advanced or metastatic solid tumors, which are refractory or intolerant to standard
  therapy or for which no standard therapy exists.
- '* Dose expansion Phase specific Inclusion Criteria:'
- 1. Participants who have histologically or cytologically confirmed diagnosis of
  relapsed or refractory, locally unresectable advanced or metastatic NSCLC, HNSCC,
  ESCC, who received at least one line of systemic treatment including anti-PD-1 or
  anti-PD-L1 therapy.
- 2. Only participants who have evaluable PD L1 expression results are eligible.
- '3. NSCLC cohort:'
- '* Documented histologically or cytologically squamous or non-squamous stage IV
  NSCLC.'
- "* Documented evidence of tumors expressing PD L1 (TPS \u2265 1%) for the determination\
  \ of PD L1 expression in NSCLC."
- '* No sensitive epidermal growth factor receptor (EGFR) mutation and anaplastic
  lymphoma kinase (ALK) rearrangement.'
- '* No known actionable genomic alterations of ROS1 rearrangement, BRAF V600E mutation,
  MET mutation, NTRK1/2/3 gene fusion, and/or RET rearrangement.'
- '4. HNSCC cohort:'
- "\u2022 Documented histologically or cytologically squamous cell carcinoma of the\
  \ head and neck. Nasopharynx is excluded."
- "\u2022 Refractory or intolerant to platinum based chemotherapy or concurrent chemoradiation."
- "* PD L1 expression: Documented evidence of Combined Positive Score (CPS) \u2265\
  \ 1 for PD L1."
- '5. ESCC cohort:'
- '* Documented histologically or cytologically squamous carcinoma.'
- "* PD L1 expression: Documented evidence of CPS \u2265 1 for PD L1."
- 'Exclude - * Dose escalation Phase and Dose expansion Phase Exclusion Criteria:'
- Exclude - 1. Participants who have received concurrent antitumor treatment or investigational
  products within 28 days or 5 half lives, whichever is shorter before the start of
  study intervention (e.g., chemotherapy, radiotherapy \[with the exception of palliative
  bone directed radiotherapy\], immunotherapy, targeted therapy, hormonal therapy,
  or cytokine therapy except for erythropoietin).
- Exclude - 2. Participants who had major surgery within 28 days before the start
  of study intervention (excluding prior diagnostic biopsy).
- "Exclude - 3. Participants who had continuance of toxicities due to prior antitumor\
  \ agents that have not resolved to Grade \u2264 1 per NCI CTCAE version 5.0, except\
  \ alopecia, \\< Grade 2 sensory neuropathy."
- Exclude - 4. Participants with a history of immune mediated AE of any grade that
  resulted in discontinuation of prior immunotherapy.
- Exclude - 5. Participants with previous malignant disease other than the target
  malignancy to be investigated in this study within the last 2 years with the exception
  of resected basal or squamous cell carcinoma of the skin, superficial bladder cancer,
  carcinoma in situ of the cervix or breast.
- 'Exclude - 6. Participants with active leptomeningeal disease or uncontrolled, untreated
  brain metastasis. Participants with a history of treated and, at the time of screening,
  stable central nervous system (CNS) metastases are eligible, provided they meet
  all the following:'
- Exclude - a. Brain imaging at screening shows no evidence of interim progression,
  participant is clinically stable for at least 2 weeks and without evidence of new
  brain metastases.
- Exclude - b. Measurable disease outside the CNS. c. No ongoing requirement for corticosteroids
  as therapy for CNS disease; off steroids 2 weeks before the first dose of AP203;
  anticonvulsants at a stable dose are allowed.
- Exclude - 7. Participants who received any organ transplantation including allogeneic
  stem cell transplantation.
- 'Exclude - 8. Participants with significant acute or chronic infections including,
  among others:'
- Exclude - o Known history of testing positive test for human immunodeficiency virus
  (HIV) or known acquired immunodeficiency syndrome (AIDS).
- 'Exclude - Note: An HIV serology test (including antigen and/or antibodies) will
  be conducted at baseline for the participants with unknown HIV status and participants
  with positive HIV test will be excluded.'
- Exclude - o Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers
  with HBV deoxyribonucleic acid (DNA) \> 500 IU/mL (or \> 2500 copies/mL) at screening.
- 'Exclude - Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated
  and stable hepatitis B (HBV DNA \< 500 IU/mL or \< 2500 copies/mL) can be enrolled.
  Participants with detectable HBsAg or detectable HBV DNA should be managed per treatment
  guidelines. Participants receiving antivirals at screening should have been treated
  for \> 2 weeks before the first dose of AP203.'
- 'Exclude - o Participants with active hepatitis C. Note: Participants with a negative
  hepatitis C virus (HCV) antibody test at screening or positive HCV antibody test
  followed by a negative HCV ribonucleic acid (RNA) test at screening are eligible.
  The HCV RNA test will be performed only for participants testing positive for HCV
  antibody. Participants receiving antivirals at screening should have been treated
  for \> 2 weeks before the first dose of AP203.'
- Exclude - 9. Participants with active or history of any autoimmune disease that
  may relapse (participants with diabetes Type I, vitiligo, psoriasis, hypo- or hyperthyroid
  disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.
- Exclude - 10. Participants with known severe hypersensitivity reactions to monoclonal
  antibodies.
- 'Exclude - 11. Participants with pregnancy or lactation period. (Note: a negative
  pregnancy test is required for WOCBP.)'
- Exclude - 12. Participants with known alcohol or drug abuse.
- "Exclude - 13. Participants with clinically significant (i.e., active) cardiovascular\
  \ disease: cerebral vascular accident/stroke (\\< 6 months prior to the first dose\
  \ of AP203), myocardial infarction (\\< 6 months prior to the first dose of AP203),\
  \ unstable angina, congestive heart failure (New York Heart Association Classification\
  \ Class \u2265 II), or serious uncontrolled cardiac arrhythmia requiring medication."
- Exclude - 14. Participants with any psychiatric condition that would prohibit the
  understanding or rendering of informed consent.
- Exclude - 15. Participants with live vaccination within 28 days of the first dose
  of AP203 and while on study is prohibited.
- Exclude - 16. Participants with all other significant diseases, in the opinion of
  the Investigator, might impair the participant's tolerance of the study intervention.
- 'Exclude - * Dose expansion Phase specific Exclusion Criterion:'
- Exclude - 1. Participants who have received prior therapy with any PD-L1 x CD137
  bispecific antibody.
short_title: A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity
  of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion
  to Selected Malignancies
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AP Biosciences Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a multi-regional, multi center, open label, first in human (FIH),
  dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability,
  pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities
  of AP203 in adult patients with locally advanced or metastatic solid tumors.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Dose-Escalation
      arm_internal_id: 0
      arm_description: Dose-Escalation
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AP203'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Dose-Expansion (Non Small Cell Lung Cancer, NSCLC)
      arm_internal_id: 1
      arm_description: Dose-Expansion (Non Small Cell Lung Cancer, NSCLC)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AP203'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Dose-Expansion (Head and Neck Squamous Cell Carcinoma, HNSCC)
      arm_internal_id: 2
      arm_description: Dose-Expansion (Head and Neck Squamous Cell Carcinoma, HNSCC)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AP203'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Dose-Expansion (Esophageal Squamous Cell Carcinoma, ESCC)
      arm_internal_id: 3
      arm_description: Dose-Expansion (Esophageal Squamous Cell Carcinoma, ESCC)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AP203'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        pdl1_status: High
        disease_status:
        - Advanced
        - Metastatic
        - Refractory
        - Recurrent
        oncotree_primary_diagnosis: _SOLID_
